Cargando…

Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation

The combination of magnetic nanoparticles with a porous silica is a composite that has attracted significant attention for potential multifunctional theranostic applications. In this study, 30 wt % CuFe(2)O(4) was impregnated into a matrix of monodispersed spherical hydrophilic silica (HYPS) nanopar...

Descripción completa

Detalles Bibliográficos
Autores principales: Jermy, B Rabindran, Ravinayagam, Vijaya, Alamoudi, Widyan A, Almohazey, Dana, Dafalla, Hatim, Hussain Allehaibi, Lina, Baykal, Abdulhadi, Toprak, Muhammet S, Somanathan, Thirunavukkarasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Beilstein-Institut 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880833/
https://www.ncbi.nlm.nih.gov/pubmed/31807407
http://dx.doi.org/10.3762/bjnano.10.214
_version_ 1783473836160712704
author Jermy, B Rabindran
Ravinayagam, Vijaya
Alamoudi, Widyan A
Almohazey, Dana
Dafalla, Hatim
Hussain Allehaibi, Lina
Baykal, Abdulhadi
Toprak, Muhammet S
Somanathan, Thirunavukkarasu
author_facet Jermy, B Rabindran
Ravinayagam, Vijaya
Alamoudi, Widyan A
Almohazey, Dana
Dafalla, Hatim
Hussain Allehaibi, Lina
Baykal, Abdulhadi
Toprak, Muhammet S
Somanathan, Thirunavukkarasu
author_sort Jermy, B Rabindran
collection PubMed
description The combination of magnetic nanoparticles with a porous silica is a composite that has attracted significant attention for potential multifunctional theranostic applications. In this study, 30 wt % CuFe(2)O(4) was impregnated into a matrix of monodispersed spherical hydrophilic silica (HYPS) nanoparticles through a simple dry impregnation technique. The chemotherapy drug cisplatin was loaded through electrostatic equilibrium adsorption over 24 h in normal saline solution. The presence of cubic spinel CuFe(2)O(4) on HYPS was confirmed through powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FTIR) and diffuse reflectance UV–vis spectroscopy (DR UV–vis) analysis. The HYPS particles showed a surface area of 170 m(2)/g, pore size of 8.3 nm and pore volume of 0.35 cm(3)/g. The cisplatin/CuFe(2)O(4)/HYPS nanoformulation showed the accumulation of copper ferrite nanoparticles on the surface and in the pores of HYPS with a surface area of 45 m(2)/g, pore size of 16 nm and pore volume of 0.18 cm(3)/g. Transmission electron microscopy (TEM) and energy dispersive X-ray (EDX) mapping analysis showed the presence of homogeneous silica particles with nanoclusters of copper ferrite distributed on the HYPS support. Vibrating sample magnetometry (VSM) analysis of CuFe(2)O(4)/HYPS showed paramagnetic behavior with a saturated magnetization value of 7.65 emu/g. DRS UV–vis analysis revealed the functionalization of cisplatin in tetrahedral and octahedral coordination in the CuFe(2)O(4)/HYPS composite. Compared to other supports such as mesocellular foam and silicalite, the release of cisplatin using the dialysis membrane technique was found to be superior when CuFe(2)O(4)/HYPS was applied as the support. An in vitro experiment was conducted to determine the potential of CuFe(2)O(4)/HYPS as an anticancer agent against the human breast cancer cell line MCF-7. The results show that the nanoparticle formulation can effectively target cancerous cells and could be an effective tumor imaging guide and drug delivery system.
format Online
Article
Text
id pubmed-6880833
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Beilstein-Institut
record_format MEDLINE/PubMed
spelling pubmed-68808332019-12-05 Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation Jermy, B Rabindran Ravinayagam, Vijaya Alamoudi, Widyan A Almohazey, Dana Dafalla, Hatim Hussain Allehaibi, Lina Baykal, Abdulhadi Toprak, Muhammet S Somanathan, Thirunavukkarasu Beilstein J Nanotechnol Full Research Paper The combination of magnetic nanoparticles with a porous silica is a composite that has attracted significant attention for potential multifunctional theranostic applications. In this study, 30 wt % CuFe(2)O(4) was impregnated into a matrix of monodispersed spherical hydrophilic silica (HYPS) nanoparticles through a simple dry impregnation technique. The chemotherapy drug cisplatin was loaded through electrostatic equilibrium adsorption over 24 h in normal saline solution. The presence of cubic spinel CuFe(2)O(4) on HYPS was confirmed through powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FTIR) and diffuse reflectance UV–vis spectroscopy (DR UV–vis) analysis. The HYPS particles showed a surface area of 170 m(2)/g, pore size of 8.3 nm and pore volume of 0.35 cm(3)/g. The cisplatin/CuFe(2)O(4)/HYPS nanoformulation showed the accumulation of copper ferrite nanoparticles on the surface and in the pores of HYPS with a surface area of 45 m(2)/g, pore size of 16 nm and pore volume of 0.18 cm(3)/g. Transmission electron microscopy (TEM) and energy dispersive X-ray (EDX) mapping analysis showed the presence of homogeneous silica particles with nanoclusters of copper ferrite distributed on the HYPS support. Vibrating sample magnetometry (VSM) analysis of CuFe(2)O(4)/HYPS showed paramagnetic behavior with a saturated magnetization value of 7.65 emu/g. DRS UV–vis analysis revealed the functionalization of cisplatin in tetrahedral and octahedral coordination in the CuFe(2)O(4)/HYPS composite. Compared to other supports such as mesocellular foam and silicalite, the release of cisplatin using the dialysis membrane technique was found to be superior when CuFe(2)O(4)/HYPS was applied as the support. An in vitro experiment was conducted to determine the potential of CuFe(2)O(4)/HYPS as an anticancer agent against the human breast cancer cell line MCF-7. The results show that the nanoparticle formulation can effectively target cancerous cells and could be an effective tumor imaging guide and drug delivery system. Beilstein-Institut 2019-11-12 /pmc/articles/PMC6880833/ /pubmed/31807407 http://dx.doi.org/10.3762/bjnano.10.214 Text en Copyright © 2019, Jermy et al. https://creativecommons.org/licenses/by/4.0https://www.beilstein-journals.org/bjnano/termsThis is an Open Access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0). Please note that the reuse, redistribution and reproduction in particular requires that the authors and source are credited. The license is subject to the Beilstein Journal of Nanotechnology terms and conditions: (https://www.beilstein-journals.org/bjnano/terms)
spellingShingle Full Research Paper
Jermy, B Rabindran
Ravinayagam, Vijaya
Alamoudi, Widyan A
Almohazey, Dana
Dafalla, Hatim
Hussain Allehaibi, Lina
Baykal, Abdulhadi
Toprak, Muhammet S
Somanathan, Thirunavukkarasu
Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation
title Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation
title_full Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation
title_fullStr Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation
title_full_unstemmed Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation
title_short Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation
title_sort targeted therapeutic effect against the breast cancer cell line mcf-7 with a cufe(2)o(4)/silica/cisplatin nanocomposite formulation
topic Full Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880833/
https://www.ncbi.nlm.nih.gov/pubmed/31807407
http://dx.doi.org/10.3762/bjnano.10.214
work_keys_str_mv AT jermybrabindran targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation
AT ravinayagamvijaya targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation
AT alamoudiwidyana targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation
AT almohazeydana targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation
AT dafallahatim targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation
AT hussainallehaibilina targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation
AT baykalabdulhadi targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation
AT toprakmuhammets targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation
AT somanathanthirunavukkarasu targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation